Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8 <sup>+</sup> T cells in patients with advanced NSCLC
Marie Naigeon, Matthieu Roulleaux Dugage, François‐Xavier Danlos, Lisa Boselli, Jean-Mehdi Jouniaux, Caroline de Oliveira, Roberto Ferrara, Boris Duchemann, Caroline Berthot, Lou Girard, Ronan Flippot, Laurence Albigès, Siham Farhane, Patrick Saulnier, Ludovic Lacroix, Frank Griscelli, Gabriel Roman, Tyler Hulett, Aurélien Marabelle, Lydie Cassard, Benjamin Besse, Nathalie Chaput
Abstract
Circulating senescent CD8 + T (T 8 sen) cells are characterized by a lack of proliferative capacities but retain cytotoxic activity and have been associated to resistance to immunotherapy in patients with advanced non–small cell lung cancer (aNSCLC). We aimed to better characterize T 8 sen and to determine which factors were associated with their accumulation in patients with aNSCLC. Circulating T 8 sen cells were characterized by a higher expression of SA-βgal and the transcription factor T-bet, confirming their senescent status. Using whole virome profiling, cytomegalovirus (CMV) was the only virus associated with T 8 sen. CMV was necessary but not sufficient to explain high accumulation of T 8 sen (T 8 sen high status). In CMV + patients, the proportion of T 8 sen cells increased with cancer progression. Last, CMV-induced T 8 sen high phenotype but not CMV seropositivity itself was associated with worse progression-free and overall survival in patients treated with anti–PD-(L)1 therapy but not with chemotherapy. Overall, CMV is the unique viral driver of T 8 sen-driven resistance to anti–PD-(L)1 antibodies in patients with aNSCLC.